CENTESSA PHARMACEUTICALS PLC - AMERICAN DEPOSITARY

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

10 Dec 2023 11:05:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

13 Nov 2023 15:05:10 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting

02 Nov 2023 08:09:52 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

25 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Additions to Senior Leadership Team

03 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

31 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

23 Aug 2023 16:08:51 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

14 Aug 2023 06:00:30 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

10 Jul 2023 07:00:04 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

24 May 2023 07:00:09 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B

22 May 2023 06:00:21 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

12 May 2023 06:00:06 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022

30 Mar 2023 06:00:28 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

27 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines

01 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

06 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

26 Jan 2023 08:08:14 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

10 Dec 2022 14:30:29 By Nasdaq GlobeNewswire